Virus Shuts Down Genzyme Facility
Genzyme Corp. has temporarily halted production at its Allston Landing production facility after a virus that impairs cell growth was detected in one of six bioreactors there.
The Cambridge-based biotechnology and pharmaceutical company, which has significant operations in Framingham and elsewhere in Central Massachusetts, said it expects the Allston facility to be operational again by the end of July.
The virus detected at the facility is known as Vesivirus 2117 and while it is known to interfere with the growth of certain cells used to produce biologic drugs, it has not been shown to cause human infection. The company said the virus was likely introduced to the facility through a nutrient used in the drug manufacturing process.
Genzyme identified the virus at the facility over the weekend and contacted federal regulators Monday morning. The company said the drugs Cerezyme and Fabrazyme are produced at the Allston facility.
WBJ Web Partners
Most Recent
Most Recent
0 Comments